Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation (NASDAQ:INCY ) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager-North America Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Dash Dhanak - Executive Vice President and Chief Scientific Officer Conference Call Participants Salveen Richter - Goldman Sachs Brian Abrahams - RBC Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Vikram Purohit - Morgan Stanley Kripa Devarakonda - Truist Securities Eva Privitera - Cowen and Company Evan Seigerman - BMO Capital Markets Jay Olson - Oppenheimer Mara Goldstein - Mizuho Securities Reni Benjamin - JMP Securities Allison Bratzel - Piper Sandler Matt Phipps - William Blair Operator Hello, and welcome to the Incyte Fourth Quarter and Full Year Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Incyte Corporation (INCY) Q4 2022 Earnings Call Transcript

Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.

Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura

Haemonetics

Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics leapt on its own beat-and-raise. The post Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone appeared first on Investor's Business Daily.

Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone

Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Tops Q4 Earnings and Revenue Estimates

Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs

AbbVie

Both companies are performing better than the broader market over the past year.

2 Steady Stocks to Buy in a Recession

Incyte (INCY) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook Incyte (INCY)

Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Incyte (INCY) is a Great Momentum Stock: Should You Buy?

Opzelura's approval in vitiligo in the USA is the main growth driver. Next driver is Opzelura's approval for the vitiligo treatment in Europe. The issue with Jakafi's LOE may be solved by the development of combo therapy and by the approval of a more comfortable frequency of usage.

Incyte: Opzelura Is The Main Growth Driver

It is useful to understand the financial implications for Incyte with its major product, JAKAFI, facing loss of exclusivity ("LOE") in 2028. 2028 is still five years away and JAKAFI continues to provide a powerful and growing stream of earnings and cash.

Incyte: Making Hay While The Sun Shines

CRISPR Therapeutics

CureVac B.V

Exelixis

Pfizer

Sarepta Therapeutics

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

7 Biotech Stocks That Will Make You Rich in 10 Years

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023.

Incyte to Report Fourth Quarter and Year-End 2022 Financial Results

Albemarle

Alaska Air Group

Delta Air Lines

Twenty-First Century Fox

Southwest Airlines

Marathon Petroleum

Regency Centers

You might think fourth quarter earnings reports are ugly if you're just looking at the S&P 500. More than a few stocks buck the trend.

9 Companies' Profit Set To Triple While S&P 500 In Free Fall

Inspire Medical Systems Inc

Madrigal Pharmaceuticals

Schrodinger 

Veeva Systems

Verona Pharma

Viatris

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.

Why These 7 Healthcare Stocks Could Soar in 2023

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

AstraZeneca

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

Ligand Pharmaceuticals

LGND vs. INCY: Which Stock Is the Better Value Option?

LGND vs. INCY: Which Stock Should Value Investors Buy Now?

Corcept Therapeutics

Innoviva

Although the sector can be quite volatile, these undervalued biotech stocks to buy offer a compelling narrative for investors. Fundamentally, the underlying narrative focuses on addressing the critical (and sometimes under-met) needs of patients suffering from various conditions and diseases.

7 Undervalued Biotech Stocks to Buy Before They Boom

These two biotechs are flying high right now.

2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond

Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks.

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq:INCY) today announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel anti-mutant calreticulin (CALR)-targeted monoclonal antibody. Pre-clinical data indicate that INCA033989 can alter disease course by reducing mutant CALR allele burden and thus may be an efficacious and safe treatment in patients with myelofibrosis (MF) and essential thrombocythemia (ET). This research was featured in the Plenary Scientific Session (Abstract #6. Session: Hematology Disease Topics & Pathways: Research, Diseases, Therapies, Myeloid Malignancies) at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-13, 2022, in New Orleans and virtually1.

Incyte's Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session

WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq:INCY) today announced new data from two of its LIMBER (Leadership In MPNs and GVHD BEyond Ruxolitinib) trials evaluating monotherapy and combination strategies using ruxolitinib (Jakafi®) with parsaclisib, its investigational phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, and INCB00928 (zilurgisertib), its activin receptor-like kinase (ALK2) inhibitor, in patients with myelofibrosis (MF). These Phase 2 and Phase 1/2 trials (Abstract #236 and Abstract #1714, respectively) were presented at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-13, 2022, in New Orleans and virtually1,2.

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022

Syndax Pharmaceuticals

– Treatment with axatilimab resulted in an overall response rate (ORR) of 67% across all patients; and an ORR of 82% in patients dosed at 1 mg/kg every 2 weeks in the Phase 2 portion of the trial – – Broad multi-organ clinical benefit including in lung, skin, and joints and fascia observed in heavily pretreated patient population – WALTHAM, Mass. and WILMINGTON, Del.

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

WILMINGTON, Del. & HONG KONG--( BUSINESS WIRE )--Incyte (NASDAQ:INCY) and CMS Aesthetics, a dermatology medical aesthetic company and subsidiary of CMS (HKEX: 00867), today announced that the companies have entered into a Collaboration and License Agreement for the development and commercialization of ruxolitinib cream, a novel cream formulation of Incyte's selective JAK inhibitor ruxolitinib, for the treatment of autoimmune and inflammatory dermatologic diseases in Greater China and certain countries in Southeast Asia.

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

News for Incyte Stock (INCY)